You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

Investigational Drug Information for MK-6482


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for MK-6482?

MK-6482 is an investigational drug.

There have been 20 clinical trials for MK-6482. The most recent clinical trial was a Phase 1 trial, which was initiated on February 27th 2020.

The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, and Kidney Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Peloton Therapeutics, Inc., and Eisai Inc.

There are five US patents protecting this investigational drug and fifty-six international patents.

Recent Clinical Trials for MK-6482
TitleSponsorPhase
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024)Merck Sharp & Dohme LLCPhase 1/Phase 2
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell RenalEisai Inc.Phase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell RenalMerck Sharp & Dohme LLCPhase 3

See all MK-6482 clinical trials

Clinical Trial Summary for MK-6482

Top disease conditions for MK-6482
Top clinical trial sponsors for MK-6482

See all MK-6482 clinical trials

US Patents for MK-6482

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MK-6482 ⤷  Try a Trial Compositions for use in treating pulmonary arterial hypertension Peloton Therapeutics, Inc. (Dallas, TX) ⤷  Try a Trial
MK-6482 ⤷  Try a Trial Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof PELOTON THERAPEUTICS, INC. (Dallas, TX) ⤷  Try a Trial
MK-6482 ⤷  Try a Trial Combination therapy of a HIF-2-.alpha. inhibitor and an immunotherapeutic agent and uses thereof Peloton Therapeutics, Inc. (Dallas, TX) ⤷  Try a Trial
MK-6482 ⤷  Try a Trial Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (Dallas, TX) ⤷  Try a Trial
MK-6482 ⤷  Try a Trial Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (Dallas, TX) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MK-6482

Drugname Country Document Number Estimated Expiration Related US Patent
MK-6482 European Patent Office EP3203991 2034-10-10 ⤷  Try a Trial
MK-6482 World Intellectual Property Organization (WIPO) WO2016057242 2034-10-10 ⤷  Try a Trial
MK-6482 Argentina AR097600 2033-09-09 ⤷  Try a Trial
MK-6482 Australia AU2014318025 2033-09-09 ⤷  Try a Trial
MK-6482 Canada CA2919397 2033-09-09 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.